

Description of Medical Areas
About the FDA Approved Listings
|
 |
Drugs Approved by the FDA (2007)
|
The following drugs have been approved this year by
the Food and Drug Administration.
Cardiology/Vascular Diseases
|
|
Fenofibrate; For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia; LifeCycle Pharma; Approved August 2007
Soliris (eculizumab); For the treatment of paroxysmal nocturnal hemoglobinuria; Alexion Pharm; Approved March 2007
Dental/Maxillofacial Surgery
|
|
Dermatology/Plastic Surgery
|
|
Altabax (retapamulin); For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes; Glaxo; Approved April 2007
Evamist (estradiol); For the treatment of moderate to severe vasomotor symptoms due to menopause; Vivus; Approved July 2007
Fenofibrate; For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia; LifeCycle Pharma; Approved August 2007
Kuvan (sapropterin dihydrochloride); For the treatment of hyperphenylalaninemia due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria; Biomarin; Approved December 2007
Soliris (eculizumab); For the treatment of paroxysmal nocturnal hemoglobinuria; Alexion Pharm; Approved March 2007
Immunology/Infectious Diseases
|
|
Altabax (retapamulin); For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes; Glaxo; Approved April 2007
Doribax (doripenem); For the treatment of intra-abdominal infections and urinary tract infections; Johnson & Johnson; Approved October 2007
Evista (raloxifene hydrochloride); For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women; Eli Lilly; Approved September 2007
Doribax (doripenem); For the treatment of intra-abdominal infections and urinary tract infections; Johnson & Johnson; Approved October 2007
Evamist (estradiol); For the treatment of moderate to severe vasomotor symptoms due to menopause; Vivus; Approved July 2007
Evista (raloxifene hydrochloride); For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women; Eli Lilly; Approved September 2007
Evista (raloxifene hydrochloride); For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women; Eli Lilly; Approved September 2007
Hycamtin (topotecan); For the treatment of small cell lung cancer; GlaxoSmithKline; Approved October 2007
Tykerb (lapatinib); For the treatment of breast cancer; GlaxoSmithKline; Approved March 2007
Altabax (retapamulin); For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes; Glaxo; Approved April 2007
Pulmonary/Respiratory Diseases
|
|
Trauma/Emergency Medicine
|
|
|
 |

Back to Centerwatch Drug Directories
|